HER2/neu amplification in breast cancer: stratification by tumor type and grade
- PMID: 12047143
- DOI: 10.1309/4NTU-N6K4-F8JF-EWRX
HER2/neu amplification in breast cancer: stratification by tumor type and grade
Abstract
The presence of HER2/neu gene amplification is prognostically and therapeutically significant for patients with breast cancer. We sought to determine whether a relationship exists between HER2/neu gene amplification and the histologic type and grade of tumor. The histologic features and corresponding HER2/neu amplification results of 401 cases of invasive breast carcinoma were reviewed. Lobular carcinomas were less likely than ductal carcinomas to have HER2/neu amplification. Amplification was less frequent in Scarff-Bloom-Richardson grade I ductal carcinomas than in grades 2 and 3. Metastatic carcinomas frequently displayed HER2/neu amplification (6/20 [30%]). Our results support a correlation between HER2/neu amplification and the histologic type and grade of breast cancer. We suggest reexamination of tumors diagnosed as Scarff-Bloom-Richardson grade I invasive ductal carcinomas or lobular carcinomas if the lesion displays HER2/neu amplification to assure the exclusion of a higher grade of lesion or of missed ductal components.
Similar articles
-
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.Mod Pathol. 2002 Dec;15(12):1318-25. doi: 10.1097/01.MP.0000038462.62634.B1. Mod Pathol. 2002. PMID: 12481013
-
Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.Breast J. 2005 Jul-Aug;11(4):278-80. doi: 10.1111/j.1075-122x.2005.21463.x. Breast J. 2005. PMID: 15982396
-
Her-2/neu gene amplification in ductal carcinoma in situ of the breast.Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):587-90. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12050101
-
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.Braz J Med Biol Res. 2013 Mar;46(3):207-16. doi: 10.1590/1414-431x20132483. Epub 2013 Mar 19. Braz J Med Biol Res. 2013. PMID: 23558859 Free PMC article. Review.
-
Molecular profiling of breast cancer.Surg Oncol Clin N Am. 2014 Jul;23(3):451-62. doi: 10.1016/j.soc.2014.03.004. Epub 2014 Apr 13. Surg Oncol Clin N Am. 2014. PMID: 24882344 Review.
Cited by
-
HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.Breast Cancer Res. 2009;11(3):R37. doi: 10.1186/bcr2322. Epub 2009 Jun 18. Breast Cancer Res. 2009. PMID: 19538720 Free PMC article.
-
The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.Oncotarget. 2017 May 16;8(32):52877-52888. doi: 10.18632/oncotarget.17907. eCollection 2017 Aug 8. Oncotarget. 2017. PMID: 28881779 Free PMC article.
-
Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study.Cancers (Basel). 2021 Jan 19;13(2):352. doi: 10.3390/cancers13020352. Cancers (Basel). 2021. PMID: 33477893 Free PMC article.
-
Heritable variation of ERBB2 and breast cancer risk.Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1252-8. doi: 10.1158/1055-9965.EPI-08-1202. Epub 2009 Mar 31. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19336545 Free PMC article.
-
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.Breast Cancer Res. 2005;7(5):R598-604. doi: 10.1186/bcr1200. Epub 2005 May 24. Breast Cancer Res. 2005. PMID: 16168103 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous